FDA Approves ITMN's Pirfenidone

Analysts at Oppenheimer & Co maintain their "buy" rating on InterMune (NASDAQ: ITMN). The target price for ITMN has been raised from $33 to $45.

According to Oppenheimer, the FDA panel has announced its decision in favor of InterMune's pirfenidone product. ITMN's stock performance is likely to benefit from the potential FDA approval, the analysts add.

ITMN’s shares closed at $23.30 yesterday. More Analyst Ratings here